Quality Assurance
QUALITY ASSURANCE
Zebutinib, the company's independently developed breakthrough cancer drug, has written a remarkable chapter for China’s original research in the API industry. Not only has this innovative medicine achieved remarkable success in the Chinese market, but it has also earned approval from the U.S. Food and Drug Administration (FDA)—a landmark moment marking the first time a China-developed anticancer drug has made its debut in the U.S. market. Beyond that, Zebutinib has expanded into mature markets such as Canada, Australia, and the European Union, while steadily advancing toward registration and commercialization in emerging regions like Southeast Asia, the Middle East, and Latin America. Meanwhile, BeiGene has formed strategic alliances with several industry leaders, leveraging their robust global networks to significantly enhance the company’s international competitiveness and deepen its market penetration worldwide.
BeiGene's Global Promotion of Zanubrutinib
2025-02-21
With its independently developed anti-cancer drug zanubrutinib, the company has written a remarkable chapter for China's original research-driven pharmaceuticals in the API industry.
undefined
Contact Us
Company Address: No. 51, West Section of Changjiang Road, South Area, Shifang Economic Development Zone, Sichuan
Copyright ©2025 Sichuan Yuxin Pharmaceutical Co., Ltd. Power By：300.cn